Prepared for Jeffrey K. | Delivered April 24, 2020
Investment Company Analysis
To Provide the employment and industry analysis of companies
BenevolentAI is a
privately held biotechnology company
Investors in the company include
two lead investors
, Temasek Holdings and Woodford Investment Management, and other investors,
Goldman Sachs, Lansdowne Partners
, Lundbeck, and Upsher Smith Laboratories.
BenevolentAI annual revenue for the 2018 fiscal year was
The company claims to be a "
in the development and application of artificial intelligence (“AI”) for scientific innovation."
According to an article by
Entrepreneur Media, Inc.
, five trends in the biotechnology industry include "
intellectual property and legal growth
, commercial model for value-based pricing for biotech products, partnerships and collaborations among new scrutiny, clinical testing and drug regularisations, and flourished innovations and investment opportunities."
Top competitors of BenevolentAI are
Lantern Pharma, CloudMedx
, Human Longevity, and Desktop Genetics.
The company promises to reduce the
time and money
spent on the development of new drugs through
. "Instead of trying to discover a new compound from scratch, BenevolentAI uses its AI system to try to find new drug candidates from
and new potential uses for existing drug candidates."
BenevolentAI generates revenue through its "bioscience machine '
' that uses algorithms and data to
locate the cause of diseases and generate insights
into them that humans otherwise could not. Its platform is being used to
for incurable diseases like motor neuron disease, Parkinson’s disease, glioblastoma, and sarcopenia."
The company's mission is to "
bring the power of humans and machines together
to make sense of and drive rapid scientific discovery."
BenevolentAI host an annual award for
medical research charities
. Winners of the charity award are aided in their
towards potentially developing new treatments and therapies through artificial intelligence.
610 assignments | 5.0